Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 18267069)

1.

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR.

Cell. 2008 Feb 8;132(3):363-74. doi: 10.1016/j.cell.2007.12.032.

2.

Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines.

Wajapeyee N, Kapoor V, Mahalingam M, Green MR.

Mol Cancer Ther. 2009 Nov;8(11):3009-14. doi: 10.1158/1535-7163.MCT-09-0470. Epub 2009 Oct 27.

3.

Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?

Decarlo K, Yang S, Emley A, Wajapeyee N, Green M, Mahalingam M.

Hum Pathol. 2010 Jun;41(6):886-94. doi: 10.1016/j.humpath.2009.12.002. Epub 2010 Mar 16.

PMID:
20233623
4.

Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.

Emley A, Yang S, Wajapeyee N, Green MR, Mahalingam M.

J Cutan Pathol. 2010 Mar;37(3):344-9. doi: 10.1111/j.1600-0560.2009.01433.x. Epub 2009 Sep 24.

PMID:
19788444
5.

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.

Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021.

6.

Secreting tumor suppression.

Chien Y, Lowe SW.

Cell. 2008 Feb 8;132(3):339-41. doi: 10.1016/j.cell.2008.01.022.

7.

Role for IGFBP7 in senescence induction by BRAF.

Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR.

Cell. 2010 May 28;141(5):746-7. doi: 10.1016/j.cell.2010.05.014. No abstract available.

8.

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.

Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M.

Pigment Cell Melanoma Res. 2008 Oct;21(5):534-44. doi: 10.1111/j.1755-148X.2008.00491.x. Epub 2007 Jul 28.

PMID:
18715233
9.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

10.

Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.

Schrama D, Kneitz H, Willmes C, Adam C, Houben R, Becker JC.

J Invest Dermatol. 2010 Mar;130(3):897-8. doi: 10.1038/jid.2009.304. Epub 2009 Oct 15. No abstract available.

11.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

12.

Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis.

Nousbeck J, Sarig O, Avidan N, Indelman M, Bergman R, Ramon M, Enk CD, Sprecher E.

J Invest Dermatol. 2010 Feb;130(2):378-87. doi: 10.1038/jid.2009.265. Epub 2009 Aug 27.

13.

BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.

Nguyen LP, Emley A, Wajapeyee N, Green MR, Mahalingam M.

Br J Dermatol. 2010 Mar;162(3):677-80. doi: 10.1111/j.1365-2133.2009.09558.x. Epub 2009 Nov 16.

14.

Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines.

Pen A, Durocher Y, Slinn J, Rukhlova M, Charlebois C, Stanimirovic DB, Moreno MJ.

Cancer Biol Ther. 2011 Oct 1;12(7):634-46. Epub 2011 Oct 1.

PMID:
21795858
15.

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.

Bhaskaran S, Dileep KV, Deepa SS, Sadasivan C, Klausner M, Krishnegowda NK, Tekmal RR, VandeBerg JL, Nair HB.

Mol Cancer Ther. 2013 Apr;12(4):361-72. doi: 10.1158/1535-7163.MCT-12-0965. Epub 2013 Mar 29.

16.

IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.

Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, Seth A.

Breast Cancer Res Treat. 2012 Jun;133(2):563-73. doi: 10.1007/s10549-011-1816-4. Epub 2011 Oct 14.

PMID:
21997538
17.

ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.

Liao YH, Hsu SM, Huang PH.

Cancer Res. 2007 Dec 15;67(24):11547-56.

18.

BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS.

Nature. 2005 Aug 4;436(7051):720-4.

19.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

20.

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.

Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, Yang F, Liu H, Thorne RF, Hersey P, Zhang XD.

Cell Death Dis. 2010 Sep 2;1:e69. doi: 10.1038/cddis.2010.48.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk